ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

Posted: May 15, 2022 at 2:13 am

FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC explore and identify funding opportunities from non-dilutive sources, such as the NIH, DOD, NSF, FDA and BARDA, as well as private foundations.

View post:
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

Related Posts